Literature DB >> 15202698

Sialorrhea: a management challenge.

Neil G Hockstein1, Daniel S Samadi, Kristin Gendron, Steven D Handler.   

Abstract

Sialorrhea (drooling or excessive salivation) is a common problem in neurologically impaired children (i.e., those with mental retardation or cerebral palsy) and in adults who have Parkinson's disease or have had a stroke. It is most commonly caused by poor oral and facial muscle control. Contributing factors may include hypersecretion of saliva, dental malocclusion, postural problems, and an inability to recognize salivary spill. Sialorrhea causes a range of physical and psychosocial complications, including perioral chapping, dehydration, odor, and social stigmatization, that can be devastating for patients and their families. Treatment of sialorrhea is best managed by a clinical team that includes primary health care providers, speech pathologists, occupational therapists, dentists, orthodontists, neurologists, and otolaryngologists. Treatment options range from conservative (i.e., observation, postural changes, biofeedback) to more aggressive measures such as medication, radiation, and surgical therapy. Anticholinergic medications, such as glycopyrrolate and scopolamine, are effective in reducing drooling, but their use may be limited by side effects. The injection of botulinum toxin type A into the parotid and submandibular glands is safe and effective in controlling drooling, but the effects fade in several months, and repeat injections are necessary. Surgical intervention, including salivary gland excision, salivary duct ligation, and duct rerouting, provides the most effective and permanent treatment of significant sialorrhea and can greatly improve the quality of life of patients and their families or caregivers.

Entities:  

Mesh:

Year:  2004        PMID: 15202698

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  25 in total

1.  Treating sialorrhea with transdermal scopolamine. Exploiting a side effect to treat an uncommon symptom in cancer patients.

Authors:  Davide Tassinari; Barbara Poggi; Manuela Fantini; Emiliano Tamburini; Sergio Sartori
Journal:  Support Care Cancer       Date:  2005-04-30       Impact factor: 3.603

2.  Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-12

Review 3.  The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.

Authors:  Klaus Seppi; Daniel Weintraub; Miguel Coelho; Santiago Perez-Lloret; Susan H Fox; Regina Katzenschlager; Eva-Maria Hametner; Werner Poewe; Olivier Rascol; Christopher G Goetz; Cristina Sampaio
Journal:  Mov Disord       Date:  2011-10       Impact factor: 10.338

4.  IncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis: an open-label single-centre study.

Authors:  Lejla Paracka; Katja Kollewe; Martin Klietz; Susanne Petri; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2019-07-17       Impact factor: 3.575

5.  Botulinum toxin in the treatment of drooling in tetraplegic patients with brain injury.

Authors:  Sung Hwa Ko; Yong Beom Shin; Ji Hong Min; Myung Jun Shin; Jae Hyeok Chang; Yong-Il Shin; Hyun-Yoon Ko
Journal:  Ann Rehabil Med       Date:  2013-12-23

6.  Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis.

Authors:  João Costa; Maria Luz Rocha; Joaquim Ferreira; Teresinha Evangelista; Miguel Coelho; Mamede de Carvalho
Journal:  J Neurol       Date:  2008-02-19       Impact factor: 4.849

7.  Comparing the Effect of Botulinum Toxin Type B Injection at Different Dosages for Patient with Drooling due to Brain Lesion.

Authors:  Hee Dong Park; Hyo Jae Kim; Sang Jun Park; Yong Min Choi
Journal:  Ann Rehabil Med       Date:  2012-12-28

8.  Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.

Authors:  Pierangelo Barbero; Marco Busso; Marco Tinivella; Carlo Alberto Artusi; Stefania De Mercanti; Angele Cucci; Andrea Veltri; Paolo Avagnina; Andrea Calvo; Adriano Chio'; Luca Durelli; Marinella Clerico
Journal:  J Neurol       Date:  2015-09-26       Impact factor: 4.849

9.  Randomized Phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions.

Authors:  Robert S Zeller; Hak-Myung Lee; Paul F Cavanaugh; Jennifer Davidson
Journal:  Ther Clin Risk Manag       Date:  2012-01-25       Impact factor: 2.423

10.  The association of drooling and health-related quality of life in children with cerebral palsy.

Authors:  Shih-Chung Chang; Chin-Kai Lin; Li-Chen Tung; Nai-Yin Chang
Journal:  Neuropsychiatr Dis Treat       Date:  2012-12-11       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.